SubHero Banner

Tecentriq® (atezolizumab) – Expanded indication

October 15, 2021 - Roche announced the FDA approval of Tecentriq (atezolizumab), as a single-agent, as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test.

Download PDF